INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,335,223 | -56.1% | 25,633 | -46.6% | 0.02% | -51.2% |
| Q2 2023 | $3,040,753 | +103.4% | 48,022 | +73.9% | 0.04% | +78.3% |
| Q1 2023 | $1,495,082 | -7.7% | 27,610 | -9.8% | 0.02% | -17.9% |
| Q4 2022 | $1,620,622 | +22.2% | 30,624 | +7.5% | 0.03% | +16.7% |
| Q3 2022 | $1,326,000 | -17.1% | 28,487 | +1.7% | 0.02% | -7.7% |
| Q2 2022 | $1,599,000 | -26.2% | 28,009 | -20.9% | 0.03% | -10.3% |
| Q1 2022 | $2,168,000 | +30.7% | 35,431 | +11.3% | 0.03% | +31.8% |
| Q4 2021 | $1,659,000 | – | 31,831 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |